Drugs / V540D
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06688058 | Dec 2024 → Nov 2026 expected | — | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V540D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06688058 ↗ |
| Modality | Vaccine | “Experimental vaccine and adjuvant administered via intramuscular (IM) injection” NCT06688058 ↗ |
| Route | Intramuscular | “Experimental vaccine and adjuvant administered via intramuscular (IM) injection” NCT06688058 ↗ |